PepsiCo, Truist, Unity Software, Rivian, Ventyx, Akero, and More Stock Market
Stocks traded higher Tuesday and Treasuries rose as dovish comments from Federal Reserve policymakers helped boost risk appetite. Wall Street continued to assess the impacts of the Israel-Hamas war as the conflict enters its fourth day.
(PEP) reported third-quarter adjusted earnings of $2.25 a share, topping analysts’ estimates of $2.15. Revenue of $23.5 billion also beat expectations. The beverage and snacks maker also raised its full-year guidance. The stock rose 1.2%.
(TFC) rose 6.2% following a report from Semafor that said the bank was in negotiations to sell the remaining 80% of its insurance brokerage business for $10 billion to private-equity firm Stone Point.
told Barron’s it doesn’t comment on rumors or speculation.
(U) rose 4.9% after the announcement that John Riccitiello would be retiring as president, chief executive and chairman of the game development platform company. Unity last month announced a controversial new price hike plan that was met with a revolt from customers. The company was forced to apologize and backtrack on some parts of the plan.
Advertisement – Scroll to Continue
(RIVN) rose 4.3% to $19.59 after shares of the electric-truck maker were upgraded to Buy from Neutral with a price target of $24. The stock fell sharply last week after Rivian announced it was selling $1.5 billion in convertible notes to raise additional cash.
(SWKS) was up 0.4% to $98.63 and
(QRVO) declined 1.8% to $93.18 after
downgraded both stocks to Sell from Neutral. Citi cut its target price on Skyworks to $87 from $116, and its target on
to $78 from $116.
(NOC), like other defense stocks, led the
on Monday following the Hamas attack on Israel. Northrop jumped 11% but was down 1.3% on Tuesday.
(LMT), which gained 8.9% on Monday, fell 0.2%.
Advertisement – Scroll to Continue
(AKRO) dropped 67% after results were mixed for its lead product candidate, a treatment for nonalcoholic steatohepatitis, a form of fatty liver disease.
Topline results released by
(VTYX) from its trial of VTX002 in patients with moderate-to-severely active ulcerative colitis were at the lower end of company guidance and the stock sank 26%.
Write to Joe Woelfel at joseph.woelfel@barrons.com
…
Read More: PepsiCo, Truist, Unity Software, Rivian, Ventyx, Akero, and More Stock Market